BioVaxys Technology Corp Chief Medical Officer David Berd joined Proactive to discuss results from its in vivo animal research study support the safety and tolerability of CoviDTH at two intradermal dose levels across a battery of clinical pathology, immunology, and histopathology evaluations.

CoviDTH is the world's first and only low-cost, disposable, point-of-care diagnostic tool that screens for a T-cell response to SARS-CoV-2, the virus that causes coronavirus, according to BioVaxys.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

Read the original:
Biovaxys says CoviDTH shows safety and tolerability in pathology and immunology evaluations - Proactive Investors USA & Canada